胥洋

副研究员，博士生导师

研究领域：药械的真实世界安全性有效性评价

电话：（010）82805019

电子邮箱：xuyang_pucri@bjmu.edu.cn

教育背景

北京大学医学博士（2018）

北京大学理学硕士（2015）

北京大学理学/经济学学士（2013）

工作经历

2023.08至今     北京大学-药事管理与临床药学系，副研究员

2021.06-2023.07  北京大学-临床研究所，副研究员

2019.02-2021.02  瑞典卡罗琳斯卡学院-临床流行病与生物统计学系，博士后

2018.09-2019.01  北京大学-健康医疗大数据国家研究院，助理研究员

社会兼职

2023.8年至今，中初保基金会医学统计专委会，委员

代表性论文（近三年）

1.Xu Y*, Evans M, Mazhar F, et al. Poor recognition and undertreatment of anemia in patients with chronic kidney disease

managed in primary care. Journal of Internal Medicine. 2023;00:1-12. (JCR Q1)

2.Xu Y*, Dong S, Fu EL, Sj？lander A, Grams ME, Selvin E, Carrero JJ: Long-term Visit-to-Visit Variability in

Hemoglobin A(1c) and Kidney-Related Outcomes in Persons With Diabetes. American journal of kidney diseases:

the official journal of the National Kidney Foundation 2023;82(3):254-256. (JCR Q1, top 5 journals in Nephrology)

3.Weng L#, Xu Y#, Yin P#, Wang Y, Chen Y, Liu W, Li S, Peng JM, Dong R, Hu XY, Jiang W, Wang CY, Gao P, Zhou MG,

Du B and for the China Critical Care Clinical Trials G. National incidence and mortality of hospitalized sepsis in China. Critical Care.

2023;27:84. (JCR Q1, top 5 journals in Critical Care and Intensive Care Medicine)

4.Xu Y#*, Fu EL#, Clase CM, Mazhar F, Jardine MJ, Carrero JJ. GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and

cardiovascular outcomes in clinical practice in type-2 diabetes.

Kidney international 2022;101:360-368 (JCR Q1, top 5 journals in Nephrology)

5.Xu Y, Fu EL, Trevisan M, Jernberg T, Sj？lander A, Clase CM, Carrero JJ. Stopping renin-angiotensin system inhibitors after

hyperkalemia and risk of adverse outcomes. American heart journal 2022;243:177-186 (JCR Q1)

6.Xu Y#, Li L#, Evans M, Xu H, Lindholm B, Carrero JJ. Burden and causes of hospital admissions and readmissions in patients

undergoing hemodialysis and peritoneal dialysis: a nationwide study. Journal of nephrology 2021;34:1949-1959 (JCR Q1)

7.Xu Y, Evans M, Soro M, Barany P, Carrero JJ. Secondary hyperparathyroidism and adverse health outcomes in adults with

chronic kidney disease. Clin Kidney J 2021;14:2213-2220 (JCR Q1)

8.Xu Y, Evans M, Barany P, James G, Sj？lander A and Carrero JJ. Factors affecting pre-end-stage kidney disease haemoglobin

control and outcomes following dialysis initiation: a nationwide study. Clin Kidney J. 2021;14:1780-1788 (JCR Q1)

9.Xu Y*, Surapaneni A, Alkas J, Evans M, Shin J-I, Selvin E, Chang A, Grams ME, Carrero JJ. Glycemic Control and the Risk

of Acute Kidney Injury in Patients With Type 2 Diabetes and Chronic Kidney Disease: Parallel Population-Based Cohort Studies

in U.S. and Swedish Routine Care. Diabetes Care 2020;43:2975-2982 (JCR Q1, top 5 journals in Endocrinology, Diabetes and Metabolism)

10.Xu Y, Wang T, Yang Z, Lin H, Shen P, Zhan S. Sulphonylureas monotherapy and risk of hospitalization for heart failure

in patients with type 2 diabetes mellitus: A population-based cohort study in China.

Pharmacoepidemiology and Drug Safety 2020;29:635-643 (JCR Q2)

荣誉奖励

2023-2024年度，第60届欧洲肾脏病年会Best Abstract